MicroRNA-21-induced dissociation of PDCD4 from rictor contributes to Akt-IKKβ-mTORC1 axis to regulate renal cancer cell invasion

Experimental Cell Research

Volumn 328, Issue 1, 2014, Pages 99-117

  Bera, Amit ^b   Das, Falguni ^b   Ghosh Choudhury, Nandini ^a,b   Kasinath, Balakuntalam S ^a,b   Abboud, Hanna E ^a,b   Choudhury, Goutam Ghosh ^a,b  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Akt kinase; MiR 21; MTOR; Renal carcinoma

Indexed keywords

ACTIN; CELL PROTEIN; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MICRORNA 21; PDCD4 PROTEIN; PROTEIN KINASE B; RICTOR PROTEIN; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; CARRIER PROTEIN; I KAPPA B KINASE; IKBKB PROTEIN, HUMAN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MICRORNA; MIRN21 MICRORNA, HUMAN; MULTIPROTEIN COMPLEX; PDCD4 PROTEIN, HUMAN; RICTOR PROTEIN, HUMAN; RNA BINDING PROTEIN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CELL INVASION; CELL MIGRATION; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PROTEIN EXPRESSION; RENAL CANCER CELL LINE; APOPTOSIS; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; GENETICS; IMMUNOPRECIPITATION; KIDNEY TUBULE; KIDNEY TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR INVASION; WESTERN BLOTTING;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CARRIER PROTEINS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; HUMANS; I-KAPPA B KINASE; IMMUNOPRECIPITATION; KIDNEY NEOPLASMS; KIDNEY TUBULES; MICRORNAS; MULTIPROTEIN COMPLEXES; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RNA-BINDING PROTEINS; TOR SERINE-THREONINE KINASES;

EID: 84908050195     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.06.022     Document Type: Article

References (129)

1. Novick A.C. Kidney cancer: past, present, and future. Urol. Oncol. 2007, 25:188-195.
2. Kaelin W.G. Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer 2009, 115:2262-2272.
3. Rankin E.B., Tomaszewski J.E., Haase V.H. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res. 2006, 66:2576-2583.
4. Dalgliesh G.L., Furge K., Greenman C., Chen L., Bignell G., Butler A., Davies H., Edkins S., Hardy C., Latimer C., Teague J., Andrews J., Barthorpe S., Beare D., Buck G., Campbell P.J., Forbes S., Jia M., Jones D., Knott H., Kok C.Y., Lau K.W., Leroy C., Lin M.L., McBride D.J., Maddison M., Maguire S., McLay K., Menzies A., Mironenko T., Mulderrig L., Mudie L., O'Meara S., Pleasance E., Rajasingham A., Shepherd R., Smith R., Stebbings L., Stephens P., Tang G., Tarpey P.S., Turrell K., Dykema K.J., Khoo S.K., Petillo D., Wondergem B., Anema J., Kahnoski R.J., Teh B.T., Stratton M.R., Futreal P.A. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010, 463:360-363.
5. Guo G., Gui Y., Gao S., Tang A., Hu X., Huang Y., Jia W., Li Z., He M., Sun L., Song P., Sun X., Zhao X., Yang S., Liang C., Wan S., Zhou F., Chen C., Zhu J., Li X., Jian M., Zhou L., Ye R., Huang P., Chen J., Jiang T., Liu X., Wang Y., Zou J., Jiang Z., Wu R., Wu S., Fan F., Zhang Z., Liu L., Yang R., Wu H., Yin W., Liu Y., Peng H., Jiang B., Feng Q., Li C., Xie J., Lu J., Kristiansen K., Li Y., Zhang X., Li S., Wang J., Yang H., Cai Z. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat. Genet. 2012, 44:17-19.
6. Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P., Davies H., Jones D., Lin M.L., Teague J., Bignell G., Butler A., Cho J., Dalgliesh G.L., Galappaththige D., Greenman C., Hardy C., Jia M., Latimer C., Lau K.W., Marshall J., McLaren S., Menzies A., Mudie L., Stebbings L., Largaespada D.A., Wessels L.F., Richard S., Kahnoski R.J., Anema J., Tuveson D.A., Perez-Mancera P.A., Mustonen V., Fischer A., Adams D.J., Rust A., Chan-on W., Subimerb C., Dykema K., Furge K., Campbell P.J., Teh B.T., Stratton M.R., Futreal P.A. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011, 469:539-542.
7. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
8. Couzin J. MicroRNAs make big impression in disease after disease. Science 2008, 319:1782-1784.
9. Huang Y., Dai Y., Yang J., Chen T., Yin Y., Tang M., Hu C., Zhang L. Microarray analysis of microRNA expression in renal clear cell carcinoma. Eur. J. Surg. Oncol. 2009, 35:1119-1123.
10. Juan D., Alexe G., Antes T., Liu H., Madabhushi A., Delisi C., Ganesan S., Bhanot G., Liou L.S. Identification of a microRNA panel for clear-cell kidney cancer. Urology 2010, 75:835-841.
11. Nakada C., Matsuura K., Tsukamoto Y., Tanigawa M., Yoshimoto T., Narimatsu T., Nguyen L.T., Hijiya N., Uchida T., Sato F., Mimata H., Seto M., Moriyama M. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J. Pathol. 2008, 216:418-427.
12. Petillo D., Kort E.J., Anema J., Furge K.A., Yang X.J., Teh B.T. MicroRNA profiling of human kidney cancer subtypes. Int J Oncol 2009, 35:109-114.
13. The Cancer Genome Atlas Research Network Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013, 499:43-49.
14. Yi Z., Fu Y., Zhao S., Zhang X., Ma C. Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues. J. Cancer Res. Clin. Oncol. 2010, 136:855-862.
15. Volinia S., Galasso M., Costinean S., Tagliavini L., Gamberoni G., Drusco A., Marchesini J., Mascellani N., Sana M.E., Abu Jarour R., Desponts C., Teitell M., Baffa R., Aqeilan R., Iorio M.V., Taccioli C., Garzon R., Di Leva G., Fabbri M., Catozzi M., Previati M., Ambs S., Palumbo T., Garofalo M., Veronese A., Bottoni A., Gasparini P., Harris C.C., Visone R., Pekarsky Y., de la Chapelle A., Bloomston M., Dillhoff M., Rassenti L.Z., Kipps T.J., Huebner K., Pichiorri F., Lenze D., Cairo S., Buendia M.A., Pineau P., Dejean A., Zanesi N., Rossi S., Calin G.A., Liu C.G., Palatini J., Negrini M., Vecchione A., Rosenberg A., Croce C.M. Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 2010, 20:589-599.
16. Bera A., Ghosh-Choudhury N., Dey N., Das F., Kasinath B.S., Abboud H.E., Choudhury G.G. NFkappaB-mediated cyclin D1 expression by microRNA-21 influences renal cancer cell proliferation. Cell Signal. 2013, 25:2575-2586.
17. Dey N., Das F., Ghosh-Choudhury N., Mandal C.C., Parekh D.J., Block K., Kasinath B.S., Abboud H.E., Choudhury G.G. microRNA-21 governs TORC1 activation in renal cancer cell proliferation and invasion. PLoS One 2012, 7:e37366.
18. Roldo C., Missiaglia E., Hagan J.P., Falconi M., Capelli P., Bersani S., Calin G.A., Volinia S., Liu C.G., Scarpa A., Croce C.M. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J. Clin. Oncol. 2006, 24:4677-4684.
19. Zhu S., Wu H., Wu F., Nie D., Sheng S., Mo Y.Y. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 2008, 18:350-359.
20. Liu Z.L., Wang H., Liu J., Wang Z.X. MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol. Cell. Biochem. 2013, 372:35-45.
21. Zhou L., Yang Z.X., Song W.J., Li Q.J., Yang F., Wang D.S., Zhang N., Dou K.F. MicroRNA-21 regulates the migration and invasion of a stem-like population in hepatocellular carcinoma. Int. J. Oncol. 2013, 43:661-669.
22. Cai X., Hagedorn C.H., Cullen B.R. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 2004, 10:1957-1966.
23. Haverty P.M., Fridlyand J., Li L., Getz G., Beroukhim R., Lohr S., Wu T.D., Cavet G., Zhang Z., Chant J. High-resolution genomic and expression analyses of copy number alterations in breast tumors. Genes Chromosomes Cancer 2008, 47:530-542.
24. Fujita S., Ito T., Mizutani T., Minoguchi S., Yamamichi N., Sakurai K., Iba H. miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J. Mol. Biol. 2008, 378:492-504.
25. Loffler D., Brocke-Heidrich K., Pfeifer G., Stocsits C., Hackermuller J., Kretzschmar A.K., Burger R., Gramatzki M., Blumert C., Bauer K., Cvijic H., Ullmann A.K., Stadler P.F., Horn F. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007, 110:1330-1333.
26. Mudduluru G., George-William J.N., Muppala S., Asangani I.A., Kumarswamy R., Nelson L.D., Allgayer H. Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer. Biosci. Rep. 2011, 31:185-197.
27. Ozsolak F., Poling L.L., Wang Z., Liu H., Liu X.S., Roeder R.G., Zhang X., Song J.S., Fisher D.E. Chromatin structure analyses identify miRNA promoters. Genes Dev. 2008, 22:3172-3183.
28. Ribas J., Lupold S.E. The transcriptional regulation of miR-21, its multiple transcripts, and their implication in prostate cancer. Cell Cycle 2010, 9:923-929.
29. Mace T.A., Collins A.L., Wojcik S.E., Croce C.M., Lesinski G.B., Bloomston M. Hypoxia induces the overexpression of microRNA-21 in pancreatic cancer cells. J. Surg. Res. 2013, 184:855-860.
30. Davis B.N., Hilyard A.C., Lagna G., Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008, 454:56-61.
31. Davis B.N., Hilyard A.C., Nguyen P.H., Lagna G., Hata A. Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. Mol. Cell 2011, 39:373-384.
32. Ferraro A., Kontos C., Boni T., Bantounas I., Siakouli D., Kosmidou V., Vlassi M., Spyridakis Y., Tsipras I., Zografos G., Pintzas A. Epigenetic regulation of miR-21 in colorectal cancer: ITGB4 as a novel miR-21 target and a three-gene network (miR-21-ITGBeta4-PCDC4) as predictor of metastatic tumor potential. Epigenetics 2013, 9.
33. Li X., Xin S., Yang D., He Z., Che X., Wang J., Chen F., Wang X., Song X. Down-regulation of PDCD4 expression is an independent predictor of poor prognosis in human renal cell carcinoma patients. J. Cancer Res. Clin. Oncol. 2012, 138:529-535.
34. Asangani I.A., Rasheed S.A., Nikolova D.A., Leupold J.H., Colburn N.H., Post S., Allgayer H. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008, 27:2128-2136.
35. Frankel L.B., Christoffersen N.R., Jacobsen A., Lindow M., Krogh A., Lund A.H. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J. Biol. Chem. 2008, 283:1026-1033.
36. Baffa R., Fassan M., Volinia S., O'Hara B., Liu C.G., Palazzo J.P., Gardiman M., Rugge M., Gomella L.G., Croce C.M., Rosenberg A. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J. Pathol. 2009, 219:214-221.
37. Hiyoshi Y., Kamohara H., Karashima R., Sato N., Imamura Y., Nagai Y., Yoshida N., Toyama E., Hayashi N., Watanabe M., Baba H. MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin. Cancer Res. 2009, 15:1915-1922.
38. Chen Y., Liu W., Chao T., Zhang Y., Yan X., Gong Y., Qiang B., Yuan J., Sun M., Peng X. MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. Cancer Lett. 2008, 272:197-205.
39. Lankat-Buttgereit B., Goke R. The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation. Biol. Cell 2009, 101:309-317.
40. Yang H.S., Cho M.H., Zakowicz H., Hegamyer G., Sonenberg N., Colburn N.H. A novel function of the MA-3 domains in transformation and translation suppressor Pdcd4 is essential for its binding to eukaryotic translation initiation factor 4A. Mol. Cell. Biol. 2004, 24:3894-3906.
41. Zakowicz H., Yang H.S., Stark C., Wlodawer A., Laronde-Leblanc N., Colburn N.H. Mutational analysis of the DEAD-box RNA helicase eIF4AII characterizes its interaction with transformation suppressor Pdcd4 and eIF4GI. RNA 2005, 11:261-274.
42. Jansen A.P., Camalier C.E., Stark C., Colburn N.H. Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity. Mol. Cancer Ther. 2004, 3:103-110.
43. Shiota M., Izumi H., Tanimoto A., Takahashi M., Miyamoto N., Kashiwagi E., Kidani A., Hirano G., Masubuchi D., Fukunaka Y., Yasuniwa Y., Naito S., Nishizawa S., Sasaguri Y., Kohno K. Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth. Cancer Res. 2009, 69:3148-3156.
44. Papagiannakopoulos T., Shapiro A., Kosik K.S. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res. 2008, 68:8164-8172.
45. Das F., Ghosh-Choudhury N., Dey N., Mandal C.C., Mahimainathan L., Kasinath B.S., Abboud H.E., Choudhury G.G. Unrestrained mammalian target of rapamycin complexes 1 and 2 increase expression of phosphatase and tensin homolog deleted on chromosome 10 to regulate phosphorylation of Akt kinase. J. Biol. Chem. 2012, 287:3808-3822.
46. Das F., Ghosh-Choudhury N., Venkatesan B., Li X., Mahimainathan L., Choudhury G.G. Akt kinase targets association of CBP with SMAD 3 to regulate TGFbeta-induced expression of plasminogen activator inhibitor-1. J. Cell. Physiol. 2008, 214:513-527.
47. Mandal C.C., Ghosh-Choudhury N., Yoneda T., Choudhury G.G. Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J. Biol. Chem. 2011, 286:11314-11327.
48. Das F., Ghosh-Choudhury N., Mahimainathan L., Venkatesan B., Feliers D., Riley D.J., Kasinath B.S., Choudhury G.G. Raptor-rictor axis in TGFbeta-induced protein synthesis. Cell Signal. 2008, 20:409-423.
49. Allgayer H. Pdcd4, a colon cancer prognostic that is regulated by a microRNA. Crit. Rev. Oncol. Hematol. 2010, 73:185-191.
50. Dey N., Das F., Mariappan M.M., Mandal C.C., Ghosh-Choudhury N., Kasinath B.S., Choudhury G.G. MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes. J. Biol. Chem. 2011, 286:25586-25603.
51. Dey N., Ghosh-Choudhury N., Kasinath B.S., Choudhury G.G. TGFbeta-stimulated microRNA-21 utilizes PTEN to orchestrate AKT/mTORC1 signaling for mesangial cell hypertrophy and matrix expansion. PLoS One 2012, 7:e42316.
52. Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12:21-35.
53. Ohne Y., Takahara T., Hatakeyama R., Matsuzaki T., Noda M., Mizushima N., Maeda T. Isolation of hyperactive mutants of mammalian target of rapamycin. J. Biol. Chem. 2008, 283:31861-31870.
54. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
55. Shibahara K., Asano M., Ishida Y., Aoki T., Koike T., Honjo T. Isolation of a novel mouse gene MA-3 that is induced upon programmed cell death. Gene 1995, 166:297-301.
56. Yang H.S., Jansen A.P., Komar A.A., Zheng X., Merrick W.C., Costes S., Lockett S.J., Sonenberg N., Colburn N.H. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol. Cell. Biol. 2003, 23:26-37.
57. Hilliard A., Hilliard B., Zheng S.J., Sun H., Miwa T., Song W., Goke R., Chen Y.H. Translational regulation of autoimmune inflammation and lymphoma genesis by programmed cell death 4. J. Immunol. 2006, 177:8095-8102.
58. Jansen A.P., Camalier C.E., Colburn N.H. Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res. 2005, 65:6034-6041.
59. Jin H., Kim T.H., Hwang S.K., Chang S.H., Kim H.W., Anderson H.K., Lee H.W., Lee K.H., Colburn N.H., Yang H.S., Cho M.H., Cho C.S. Aerosol delivery of urocanic acid-modified chitosan/programmed cell death 4 complex regulated apoptosis, cell cycle, and angiogenesis in lungs of K-ras null mice. Mol. Cancer Ther. 2006, 5:1041-1049.
60. Yao Q., Xu H., Zhang Q.Q., Zhou H., Qu L.H. MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells. Biochem. Biophys. Res. Commun. 2009, 388:539-542.
61. Wen Y.H., Shi X., Chiriboga L., Matsahashi S., Yee H., Afonja O. Alterations in the expression of PDCD4 in ductal carcinoma of the breast. Oncol. Rep. 2007, 18:1387-1393.
62. Zhang H., Ozaki I., Mizuta T., Hamajima H., Yasutake T., Eguchi Y., Ideguchi H., Yamamoto K., Matsuhashi S. Involvement of programmed cell death 4 in transforming growth factor-beta1-induced apoptosis in human hepatocellular carcinoma. Oncogene 2006, 25:6101-6112.
63. Gao F., Wang X., Zhu F., Wang Q., Zhang X., Guo C., Zhou C., Ma C., Sun W., Zhang Y., Chen Y.H., Zhang L. PDCD4 gene silencing in gliomas is associated with 5'CpG island methylation and unfavourable prognosis. J. Cell. Mol. Med. 2009, 13:4257-4267.
64. Fan H., Zhao Z., Quan Y., Xu J., Zhang J., Xie W. DNA methyltransferase 1 knockdown induces silenced CDH1 gene reexpression by demethylation of methylated CpG in hepatocellular carcinoma cell line SMMC-7721. Eur. J. Gastroenterol. Hepatol. 2007, 19:952-961.
65. Appl H., Klempnauer K.H. Targeted disruption of c-myb in the chicken pre B-cell line DT40. Oncogene 2002, 21:3076-3081.
66. Pan X., Wang Z.X., Wang R. MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol. Ther. 2010, 10:1224-1232.
67. Wang Y.Q., Guo R.D., Guo R.M., Sheng W., Yin L.R. MicroRNA-182 promotes cell growth, invasion, and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas. J. Cell. Biochem. 2013, 114:1464-1473.
68. Denby L., Ramdas V., McBride M.W., Wang J., Robinson H., McClure J., Crawford W., Lu R., Hillyard D.Z., Khanin R., Agami R., Dominiczak A.F., Sharpe C.C., Baker A.H. miR-21 and miR-214 are consistently modulated during renal injury in rodent models. Am. J. Pathol. 2011, 179:661-672.
69. Godwin J.G., Ge X., Stephan K., Jurisch A., Tullius S.G., Iacomini J. Identification of a microRNA signature of renal ischemia reperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:14339-14344.
70. Kato M., Arce L., Natarajan R. MicroRNAs and their role in progressive kidney diseases. Clin. J. Am. Soc. Nephrol. 2009, 4:1255-1266.
71. Zarjou A., Yang S., Abraham E., Agarwal A., Liu G. Identification of a microRNA signature in renal fibrosis: role of miR-21. Am. J. Physiol. Renal Physiol. 2011, 301:F793-801.
72. Kato M., Natarajan R. MicroRNA circuits in transforming growth factor-beta actions and diabetic nephropathy. Semin. Nephrol. 2012, 32:253-260.
73. Saal S., Harvey S.J. MicroRNAs and the kidney: coming of age. Curr. Opin. Nephrol. Hypertens. 2009, 18:317-323.
74. Sataranatarajan K., Feliers D., Mariappan M.M., Lee H.J., Lee M.J., Day R.T., Yalamanchili H.B., Choudhury G.G., Barnes J.L., Van Remmen H., Richardson A., Kasinath B.S. Molecular events in matrix protein metabolism in the aging kidney. Aging Cell 2012, 11:1065-1073.
75. Neal C.S., Michael M.Z., Rawlings L.H., Van der Hoek M.B., Gleadle J.M. The VHL-dependent regulation of microRNAs in renal cancer. BMC Med. 2010, 8:64.
76. Powers M.P., Alvarez K., Kim H.J., Monzon F.A. Molecular classification of adult renal epithelial neoplasms using microRNA expression and virtual karyotyping. Diagn. Mol. Pathol. 2011, 20:63-70.
77. Kumarswamy R., Volkmann I., Thum T. Regulation and function of miRNA-21 in health and disease. RNA Biol. 2011, 8:706-713.
78. Hatley M.E., Patrick D.M., Garcia M.R., Richardson J.A., Bassel-Duby R., van Rooij E., Olson E.N. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 2010, 18:282-293.
79. Lu T.X., Lim E.J., Itskovich S., Besse J.A., Plassard A.J., Mingler M.K., Rothenberg J.A., Fulkerson P.C., Aronow B.J., Rothenberg M.E. Targeted ablation of miR-21 decreases murine eosinophil progenitor cell growth. PLoS One 2013, 8:e59397.
80. Ma X., Kumar M., Choudhury S.N., Becker Buscaglia L.E., Barker J.R., Kanakamedala K., Liu M.F., Li Y. Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:10144-10149.
81. Medina P.P., Nolde M., Slack F.J. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010, 467:86-90.
82. Mei Y., Bian C., Li J., Du Z., Zhou H., Yang Z., Zhao R.C. miR-21 modulates the ERK-MAPK signaling pathway by regulating SPRY2 expression during human mesenchymal stem cell differentiation. J. Cell. Biochem. 2013, 114:1374-1384.
83. Niu Z., Goodyear S.M., Rao S., Wu X., Tobias J.W., Avarbock M.R., Brinster R.L. MicroRNA-21 regulates the self-renewal of mouse spermatogonial stem cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:12740-12745.
84. Polajeva J., Swartling F.J., Jiang Y., Singh U., Pietras K., Uhrbom L., Westermark B., Roswall P. miRNA-21 is developmentally regulated in mouse brain and is co-expressed with SOX2 in glioma. BMC Cancer 2012, 12:378.
85. Han M., Liu M., Wang Y., Chen X., Xu J., Sun Y., Zhao L., Qu H., Fan Y., Wu C. Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. PLoS One 2012, 7:e39520.
86. Zhang S., Wan Y., Pan T., Gu X., Qian C., Sun G., Sun L., Xiang Y., Wang Z., Shi L. MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide. J. Mol. Neurosci. 2012, 47:346-356.
87. Han M., Liu M., Wang Y., Mo Z., Bi X., Liu Z., Fan Y., Chen X., Wu C. Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells. Mol. Cell. Biochem. 2012, 363:427-436.
88. Han M., Wang Y., Liu M., Bi X., Bao J., Zeng N., Zhu Z., Mo Z., Wu C., Chen X. MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1alpha expression in third-sphere forming breast cancer stem cell-like cells. Cancer Sci. 2012, 103:1058-1064.
89. Castaneda C.A., Cortes-Funes H., Gomez H.L., Ciruelos E.M. The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer. Cancer Metastasis Rev. 2010, 29:751-759.
90. Vadas O., Burke J.E., Zhang X., Berndt A., Williams R.L. Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci. Signal. 2011, 4.
91. Cully M., You H., Levine A.J., Mak T.W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 2006, 6:184-192.
92. Petrella B.L., Brinckerhoff C.E. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma. Cancer Biol. Ther. 2009, 8:1389-1401.
93. Aggarwal B.B., Sung B. NF-kappaB in cancer: a matter of life and death. Cancer Discov. 2011, 1:469-471.
94. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
95. Hiraga T., Myoui A., Hashimoto N., Sasaki A., Hata K., Morita Y., Yoshikawa H., Rosen C.J., Mundy G.R., Yoneda T. Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Res. 2012, 72:4238-4249.
96. Li S., Kendall S.E., Raices R., Finlay J., Covarrubias M., Liu Z., Lowe G., Lin Y.H., Teh Y.H., Leigh V., Dhillon S., Flanagan S., Aboody K.S., Glackin C.A. TWIST1 associates with NF-kappaB subunit RELA via carboxyl-terminal WR domain to promote cell autonomous invasion through IL8 production. BMC Biol. 2012, 10:73.
97. Matusan-Ilijas K., Damante G., Fabbro D., Dordevic G., Hadzisejdic I., Grahovac M., Maric I., Spanjol J., Grahovac B., Jonjic N., Lucin K. Osteopontin expression correlates with nuclear factor-kappaB activation and apoptosis downregulation in clear cell renal cell carcinoma. Pathol. Res. Pract. 2011, 207:104-110.
98. Oya M., Ohtsubo M., Takayanagi A., Tachibana M., Shimizu N., Murai M. Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene 2001, 20:3888-3896.
99. Yang H.S., Jansen A.P., Nair R., Shibahara K., Verma A.K., Cmarik J.L., Colburn N.H. A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-kappaB or ODC transactivation. Oncogene 2001, 20:669-676.
100. Heimberg H., Heremans Y., Jobin C., Leemans R., Cardozo A.K., Darville M., Eizirik D.L. Inhibition of cytokine-induced NF-kappaB activation by adenovirus-mediated expression of a NF-kappaB super-repressor prevents beta-cell apoptosis. Diabetes 2001, 50:2219-2224.
101. Kim S., Millet I., Kim H.S., Kim J.Y., Han M.S., Lee M.K., Kim K.W., Sherwin R.S., Karin M., Lee M.S. NF-kappa B prevents beta cell death and autoimmune diabetes in NOD mice. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:1913-1918.
102. Chang I., Kim S., Kim J.Y., Cho N., Kim Y.H., Kim H.S., Lee M.K., Kim K.W., Lee M.S. Nuclear factor kappaB protects pancreatic beta-cells from tumor necrosis factor-alpha-mediated apoptosis. Diabetes 2003, 52:1169-1175.
103. Giannoukakis N., Rudert W.A., Trucco M., Robbins P.D. Protection of human islets from the effects of interleukin-1beta by adenoviral gene transfer of an Ikappa B repressor. J. Biol. Chem. 2000, 275:36509-36513.
104. Sheedy F.J., Palsson-McDermott E., Hennessy E.J., Martin C., O'Leary J.J., Ruan Q., Johnson D.S., Chen Y., O'Neill L.A. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat. Immunol. 2010, 11:141-147.
105. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
106. Menon S., Manning B.D. Common corruption of the mTOR signaling network in human tumors. Oncogene 2008, 27(Suppl 2):S43-S51.
107. Feng Z., Zhang H., Levine A.J., Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:8204-8209.
108. Howell J.J., Ricoult S.J., Ben-Sahra I., Manning B.D. A growing role for mTOR in promoting anabolic metabolism. Biochem. Soc. Trans. 2013, 41:906-912.
109. Laplante M., Sabatini D.M. Regulation of mTORC1 and its impact on gene expression at a glance. J. Cell Sci. 2013, 126:1713-1719.
110. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
111. Hietakangas V., Cohen S.M. TOR complex 2 is needed for cell cycle progression and anchorage-independent growth of MCF7 and PC3 tumor cells. BMC Cancer 2008, 8:282.
112. Masri J., Bernath A., Martin J., Jo O.D., Vartanian R., Funk A., Gera J. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res. 2007, 67:11712-11720.
113. Atkins M.B., Hidalgo M., Stadler W.M., Logan T.F., Dutcher J.P., Hudes G.R., Park Y., Liou S.H., Marshall B., Boni J.P., Dukart G., Sherman M.L. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 2004, 22:909-918.
114. Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., Grunwald V., Thompson J.A., Figlin R.A., Hollaender N., Urbanowitz G., Berg W.J., Kay A., Lebwohl D., Ravaud A. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
115. Traynor K. New oral treatment for kidney cancer approved. Am. J. Health Syst. Pharm. 2009, 66:788.
116. Kang S.A., Pacold M.E., Cervantes C.L., Lim D., Lou H.J., Ottina K., Gray N.S., Turk B.E., Yaffe M.B., Sabatini D.M. mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science 2013, 341:1236566.
117. Harrington L.S., Findlay G.M., Gray A., Tolkacheva T., Wigfield S., Rebholz H., Barnett J., Leslie N.R., Cheng S., Shepherd P.R., Gout I., Downes C.P., Lamb R.F. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 2004, 166:213-223.
118. Shah O.J., Wang Z., Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 2004, 14:1650-1656.
119. Sancak Y., Thoreen C.C., Peterson T.R., Lindquist R.A., Kang S.A., Spooner E., Carr S.A., Sabatini D.M. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell 2007, 25:903-915.
120. Li Y., Corradetti M.N., Inoki K., Guan K.L. TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem. Sci. 2004, 29:32-38.
121. Inoki K., Li Y., Zhu T., Wu J., Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 2002, 4:648-657.
122. Zinzalla V., Stracka D., Oppliger W., Hall M.N. Activation of mTORC2 by association with the ribosome. Cell 2011, 144:757-768.
123. Luan F.L., Ding R., Sharma V.K., Chon W.J., Lagman M., Suthanthiran M. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int. 2003, 63:917-926.
124. Zhou H., Huang S. mTOR signaling in cancer cell motility and tumor metastasis. Crit. Rev. Eukaryot. Gene Expr. 2010, 20:1-16.
125. Dan H.C., Cooper M.J., Cogswell P.C., Duncan J.A., Ting J.P., Baldwin A.S. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev. 2008, 22:1490-1500.
126. Lee D.F., Kuo H.P., Chen C.T., Hsu J.M., Chou C.K., Wei Y., Sun H.L., Li L.Y., Ping B., Huang W.C., He X., Hung J.Y., Lai C.C., Ding Q., Su J.L., Yang J.Y., Sahin A.A., Hortobagyi G.N., Tsai F.J., Tsai C.H., Hung M.C. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 2007, 130:440-455.
127. Dan H.C., Baldwin A.S. Differential involvement of IkappaB kinases alpha and beta in cytokine- and insulin-induced mammalian target of rapamycin activation determined by Akt. J. Immunol. 2008, 180:7582-7589.
128. Ponting C.P. Novel eIF4G domain homologues linking mRNA translation with nonsense-mediated mRNA decay. Trends Biochem. Sci. 2000, 25:423-426.
129. Dorrello N.V., Peschiaroli A., Guardavaccaro D., Colburn N.H., Sherman N.E., Pagano M. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 2006, 314:467-471.